Berlin-based digital health company Fosanis, the developer of Mika, Germany's first prescription DTx for all oncological indications, closed a series A funding round of more than 10 million EUR. Besides existing shareholders such as Ananda Impact Ventures, three new investors joined in the latest financing round: lead investor Swiss company Debiopharm Innovation Fund, Ship2B Ventures from Spain and venture capital firm Equity Pitcher.

The company is currently building an ESG ecosystem based on 3 key pillars, namely GoLearn (education), GoNetwork (structured advocacy) and GoInvest (deal flow platform for sustainable investments), to enable actions on sustainable development.

https://www.helloaria.eu/

Energy

Sustainability

Lending And Investments

Data And Analytics

Information Technology

Education

Financial Services

Hong Kong

Aria

Series A Financing Round Lays Foundation For International Growth Of Digital Cancer Therapeutics Mika

Series A Financing Round Lays Foundation For International Growth Of Digital Cancer Therapeutics Mika

Description

Company Information

Related People

Series A Financing Round Lays Foundation For International Growth Of Digital Cancer Therapeutics Mika

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information